1979
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Weiss R, DeVita V. Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals Of Internal Medicine 1979, 91: 251-60. PMID: 380437, DOI: 10.7326/0003-4819-91-2-251.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrimary treatment programGroup of patientsAdvanced diseaseTherapy regimensPrimary lesionSurgical removalAdult malignanciesPalliative treatmentTreatment resultsClinical trialsHuman trialsCancer mortalityChemotherapyMalignancyTreatment programsTreatmentRegimensPatientsLesionsCancer
1977
Malignant melanoma: prognostic factors and therapeutic results.
DeVita V, Fisher R. Malignant melanoma: prognostic factors and therapeutic results. West Virginia Medical Journal 1977, 73: 167-72. PMID: 268079.Peer-Reviewed Original Research
1976
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Canellos G, DeVita V, Gold G, Chabner B, Schein P, Young R. Combination chemotherapy for advanced breast cancer: response and effect on survival. Annals Of Internal Medicine 1976, 84: 389-92. PMID: 1259283, DOI: 10.7326/0003-4819-84-4-389.Peer-Reviewed Original ResearchConceptsMedian survivalBreast cancerFunctional liver impairmentPrevious cytotoxic therapyAdvanced breast cancerMetastatic breast cancerHormonal therapyLiver impairmentMetastatic diseasePartial responseCombination chemotherapyComplete responseNodal metastasisCytotoxic therapyEndocrine ablationPatientsFourteenth daySoft tissueEighth daySurvivalTherapyCancerMonthsDaysResponsive sitesNatural history of malignant melanoma as related to therapy.
DeVita V, Fisher R. Natural history of malignant melanoma as related to therapy. Journal Of The National Cancer Institute 1976, 60: 153-7. PMID: 1260773.Peer-Reviewed Original Research
1975
SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION
Canellos G, Arseneau J, Devita V, Whang-Peng J, Johnson R. SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. The Lancet 1975, 305: 947-949. PMID: 48122, DOI: 10.1016/s0140-6736(75)92007-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellChromosome AberrationsColonic NeoplasmsFemaleFibrosarcomaHodgkin DiseaseHumansImmunosuppression TherapyLeukemia, Monocytic, AcuteLeukemia, Myeloid, AcuteLung NeoplasmsMaleMiddle AgedNeoplasmsNeoplasms, Radiation-InducedRadiotherapyRemission, SpontaneousSkin NeoplasmsConceptsIntensive radiotherapyCombination chemotherapyPatients treated with standard chemotherapyCourse of Hodgkin's diseaseRelapse of diseaseAcute myeloid leukemiaMan-years of follow-upMode of treatmentMechanisms of oncogenesisStandard chemotherapyHodgkin's diseaseChromosomal abnormalitiesMyeloid leukemiaImmunosuppressive effectsRadiotherapyFollow-upChemotherapyTumorHigh riskCellular effectsPatientsDiseaseIncidenceTreatmentRisk
1972
Clinical study with bleomycin: Tolerance to twice weekly dosage
Ohnuma T, Selawry O, Holland J, DeVita V, Shedd D, Hansen H, Muggia F. Clinical study with bleomycin: Tolerance to twice weekly dosage. Cancer 1972, 30: 914-922. PMID: 4116909, DOI: 10.1002/1097-0142(197210)30:4<914::aid-cncr2820300409>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaDose levelsObjective tumor responseBody surface areaTherapeutic dose levelsOptimal dose levelNew antineoplastic agentsPulmonary infiltratesTransient hypertensionUrinary burningAbdominal distentionComplete remissionHematologic toxicityCutaneous toxicityWeekly dosesProlonged courseAdditional patientsPatient toleranceSkin toxicityMalignant neoplasmsTesticular carcinomaTumor responseTumor regressionWeekly dosage
1970
CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO
Young R, DeVita V. CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO. Cell Proliferation 1970, 3: 285-290. PMID: 5523056, DOI: 10.1111/j.1365-2184.1970.tb00273.x.Peer-Reviewed Original Research